Pediatric Hematology/Oncology

Study: Treatment of Children with All Stages of Hepatoblastoma

Treatment of Children with All Stages of Hepatoblastoma.


COG # AHEP0731


This study is for patients with hepatoblastoma. Hepatoblastoma is a type of cancer that occurs in the liver. Researchers now know that there are some features of hepatoblastoma that may help predict how children will respond to therapy. Factors that affect how well a child with hepatoblastoma will do include:

  • Whether the tumor can be completely removed by surgery,
  • Whether the tumor or cancer cells have spread to other parts of the body (metastasized),
  • How quickly a protein in the blood called alpha-fetoprotein (AFP) is decreased during treatment for hepatoblastoma. AFP is often very high in certain cancers, such as hepatoblastoma.
  • The appearance of tumor cells under the microscope.

Researchers know that children need different treatments based on the factors associated with the tumor. These factors determine the risk of the tumor coming back. This study will group children as having a very low-risk, low-risk, intermediate-risk or high-risk disease. This study will try to learn more about the factors that lead to a good or a poor chance of recovery (prognosis) for children. We want to develop effective treatments that will increase the overall success rate and decrease the side effects of the therapy.


  • Patients must be ≤ 21 years of age at the time of diagnosis.
  • Patients may have had surgical resection of some or all sites of hepatoblastoma prior to enrollment.
  • Patients must be newly diagnosed with histologically-proven hepatoblastoma except for patients too ill to undergo a biopsy safely.

Primary Investigator(s)

Mandy Atkinson, M.D.

Contact Information

Wendy McCarty, Clinical Research Coordinator
Office: 540-981-7376